Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2597

1.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

2.

Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese.

Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB.

J Lipid Res. 2007 Nov;48(11):2499-505. Epub 2007 Aug 13.

3.

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group.

Circulation. 2001 Sep 4;104(10):1108-13.

4.

Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?

Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB.

J Am Coll Cardiol. 2006 Sep 5;48(5):973-9. Epub 2006 Aug 17.

6.

Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.

Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PW.

J Lipid Res. 1994 May;35(5):779-92.

7.
8.

Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.

St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B.

Am J Cardiol. 2006 Apr 1;97(7):997-1001. Epub 2006 Feb 13.

PMID:
16563904
9.

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).

Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group.

Ann Med. 2008;40(6):456-64.

PMID:
19160529
10.

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.

Circulation. 2006 Mar 28;113(12):1556-63. Epub 2006 Mar 13.

12.

Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).

Holme I, Aastveit AH, Jungner I, Walldius G.

J Intern Med. 2008 Jul;264(1):30-8. doi: 10.1111/j.1365-2796.2008.01925.x. Epub 2008 Feb 21.

13.

Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.

Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J.

Circulation. 2004 Nov 2;110(18):2824-30. Epub 2004 Oct 18.

14.

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM.

Am J Cardiol. 2006 Nov 15;98(10):1363-8. Epub 2006 Sep 29.

PMID:
17134630
16.

Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.

Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB.

Diabetes Care. 2004 Aug;27(8):1991-7.

PMID:
15277429
17.

Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B.

Am J Cardiol. 2003 May 15;91(10):1173-7.

PMID:
12745098
18.
19.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.

20.

Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction.

Farwell WR, Sesso HD, Buring JE, Gaziano JM.

Am J Cardiol. 2005 Oct 15;96(8):1129-34. Epub 2005 Aug 29.

PMID:
16214451

Supplemental Content

Support Center